Condition: melanoma


rs11076650 in AFG3L1P gene and melanoma PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

PMID 19578364 2009 Genome-wide association study identifies three loci associated with melanoma risk.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs1636744 in AHR gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs1057519804 in AKT1 gene and melanoma PMID 24265152 2014 A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

rs1801516 in ATM gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs17305657 in BPIFA3 gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 18488026 2008 Common sequence variants on 20q11.22 confer melanoma susceptibility.

rs1057519718 in BRAF gene and melanoma PMID 12068308 2002 Mutations of the BRAF gene in human cancer.

PMID 20141835 2010 Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

PMID 14679157 2003 Determinants of BRAF mutations in primary melanomas.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 16096377 2005 Analysis of BRAF mutation in primary and metastatic melanoma.

PMID 21639808 2011 Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.

PMID 22048237 2012 Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

PMID 22389471 2012 To identify determinants of acquired resistance to GSK2118436 and strategies to overcome the resistance, we isolated GSK2118436 drug-resistant clones from the A375 BRAF(V600E) and the YUSIT1 BRAF(V600K) melanoma cell lines.

PMID 19404918 2009 Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder.

PMID 20818844 2010 In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.

PMID 22536370 2012 Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

PMID 21156289 2010 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

PMID 23020132 2012 Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

PMID 23918947 2013 Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

PMID 20630094 2010 Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

PMID 23031422 2012 Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.

PMID 24508103 2014 Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

PMID 22351686 2012 The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

PMID 22972589 2013 Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

PMID 22805292 2012 Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

PMID 22608338 2012 Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumours, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.

PMID 22997239 2012 Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inhibitors on melanoma cell viability in vitro and growth in athymic nude Foxn1 ( nu ) mice (P = .03 when mean tumor volume at day 13 was compared for BRAF(V600E) inhibitor vs BRAF(V600E) inhibitor plus CDK2/4 inhibition; P = .02 when mean tumor volume was compared for MEK inhibitor vs MEK inhibitor plus CDK2/4 inhibition; P values were calculated by a two-sided Welch t test; n = 4-8 mice per group).

PMID 22356324 2012 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

PMID 24586605 2014 BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.

PMID 26678033 2016 Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

PMID 25370471 2015 A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.

PMID 22735384 2012 Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF(V600E) mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m(2) intravenously every 3 weeks).

PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

PMID 24583796 2014 Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.

PMID 22663011 2012 Improved survival with MEK inhibition in BRAF-mutated melanoma.

PMID 24576830 2014 Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

PMID 24388723 2014 Prognostic value of BRAF mutations in localized cutaneous melanoma.

PMID 23317446 2013 Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.

PMID 23237741 2013 We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.

PMID 25656898 2015 Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.

PMID 24508103 2014 Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

PMID 22735384 2012 Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

PMID 23248257 2013 Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

PMID 21639808 2011 Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

PMID 20818844 2010 Inhibition of mutated, activated BRAF in metastatic melanoma.

PMID 22608338 2012 Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

PMID 20630094 2010 Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

PMID 20551065 2010 RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

PMID 2872605 1986 Acute effects of some volatile nitrites on motor performance and lethality in mice.

PMID 18794803 2009 Knockdown of CRAF using a lentiviral shRNA suppressed both Bcl-2 expression and induced apoptosis in the D594G melanoma line but not in a V600E-mutated line.

PMID 24918823 2014 Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

PMID 23273605 2013 Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.

PMID 18794803 2009 These G469E- and D594G-mutated melanomas were found to exhibit constitutive levels of phospho-extracellular signal-regulated kinase (pERK) and low levels of phospho-mitogen-activated protein kinase/ERK kinase (pMEK) and were resistant to MEK inhibition.

PMID 24710085 2015 BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma.

PMID 23833300 2013 Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

PMID 22649091 2012 Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

PMID 22798288 2012 This study shows that cells harboring BRAF(L597R) mutants are sensitive to MEK inhibitor treatment, providing a rationale for routine screening and therapy of BRAF(L597R)-mutant melanoma.

PMID 2493360 1989 [Long-term results following surgery or radioiodine treatment of solitary autonomous adenoma of the thyroid gland].

PMID 23715574 2013 Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

PMID 19238210 2009 Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

PMID 21483012 2011 Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

PMID 12460919 2002 Missense mutations of the BRAF gene in human lung adenocarcinoma.

PMID 19010912 2008 Genetic predictors of MEK dependence in non-small cell lung cancer.

PMID 12460918 2002 BRAF and RAS mutations in human lung cancer and melanoma.

PMID 22798288 2012 BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

PMID 23715574 2013 Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

PMID 18060073 2007 Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.

PMID 20551065 2010 Our findings offer evidence of the potent antitumor activity of RG7204 against melanomas harboring the mutant BRAF(V600E) gene.

PMID 23317446 2013 Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.

PMID 23524406 2013 Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

PMID 23031422 2012 Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.

PMID 22743296 2012 A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

PMID 21750866 2011 NRAS and BRAF mutation frequency in primary oral mucosal melanoma.

rs10931936 in CASP8 gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

rs258322 in CDK10 gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 24980573 2014 Identification of a melanoma susceptibility locus and somatic mutation in TET2.

PMID 19578364 2009 Genome-wide association study identifies three loci associated with melanoma risk.

PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

rs104894340 in CDK4 gene and melanoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs291671 in CDK5RAP1 gene and melanoma PMID 18488026 2008 Common sequence variants on 20q11.22 confer melanoma susceptibility.

rs6914598 in CDKAL1 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs121913386 in CDKN2A gene and melanoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 21609436 2011 Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.

rs401681 in CLPTM1L gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

rs1057519837 in CTNNB1 gene and melanoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 15133491 2004 Genetic and epigenetic alterations of the APC gene in malignant melanoma.

PMID 11930117 2002 Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines.

PMID 11351304 2001 Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.

PMID 10027390 1999 Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.

PMID 11950921 2002 Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.

PMID 9065403 1997 Stabilization of beta-catenin by genetic defects in melanoma cell lines.

PMID 12124804 2002 Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC.

PMID 19234609 2009 Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.

rs7412746 in CTXND2 gene and melanoma PMID 21983785 2011 Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs10852628 in DBNDD1 gene and melanoma PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

rs4785751 in DEF8 gene and melanoma PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

rs202247795 in ERBB4 gene and melanoma PMID 19718025 2009 Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

rs1035142 in FLACC1 gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs16953002 in FTO gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 23455637 2013 A variant in FTO shows association with melanoma risk not due to BMI.

rs1057519742 in GNA11 gene and melanoma PMID 22808163 2012 Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

PMID 2549426 1989 GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

PMID 1328859 1992 Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells.

PMID 21083380 2010 Mutations in GNA11 in uveal melanoma.

PMID 22733540 2012 Activating Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present in approximately 80% of uveal melanomas.

rs121913492 in GNAQ gene and melanoma PMID 22808163 2012 Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

PMID 22253748 2012 The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.

PMID 21083380 2010 Mutations in GNA11 in uveal melanoma.

PMID 19078957 2009 Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

PMID 18719078 2008 Oncogenic mutations in GNAQ occur early in uveal melanoma.

PMID 1328859 1992 Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells.

PMID 22733540 2012 Activating Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present in approximately 80% of uveal melanomas.

PMID 2549426 1989 GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

PMID 22653968 2012 Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.

rs1129038 in HERC2 gene and melanoma PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

rs104894230 in HRAS;LRRC56 gene and melanoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

rs12380505 in KHSRPP1 gene and melanoma PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

rs1057519702 in KIT gene and melanoma PMID 21131919 2011 Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.

PMID 24661573 2014 Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations.

PMID 24531699 2014 The GIST of targeted therapy for malignant melanoma.

PMID 21969494 2011 Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.

PMID 22357254 2012 Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

PMID 21569090 2011 KIT amplification and gene mutations in acral/mucosal melanoma in Korea.

PMID 11276010 2001 Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.

PMID 18955458 2008 Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

PMID 15790786 2005 Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

PMID 21690468 2011 Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

PMID 9438854 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

PMID 20088873 2010 Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.

PMID 23775962 2013 Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

PMID 7530509 1995 Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.

PMID 21642685 2011 KIT as a therapeutic target in metastatic melanoma.

PMID 23582185 2013 Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

PMID 22261812 2012 Sunitinib therapy for melanoma patients with KIT mutations.

PMID 19812602 2010 Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.

PMID 17372901 2007 L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

PMID 18980976 2008 KIT gene mutations and copy number in melanoma subtypes.

PMID 18510589 2008 Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

PMID 18936790 2008 Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.

PMID 18421059 2008 Major response to imatinib mesylate in KIT-mutated melanoma.

PMID 19671763 2009 Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

PMID 16741525 2006 Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis.

PMID 16908931 2006 Somatic activation of KIT in distinct subtypes of melanoma.

PMID 20545949 2011 Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb.

PMID 19671763 2009 We have identified the first human melanoma cell line with an endogenous L576P mutation, the most common KIT mutation in melanoma ( approximately 30-40%).

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 19996579 2010 Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.

PMID 17372901 2007 L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

PMID 22932406 2012 [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].

PMID 16046538 2005 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

PMID 24755198 2014 A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.

PMID 21159146 2011 V559A and N822I double KIT mutant melanoma with predictable response to imatinib?

PMID 22355224 2011 "Study of the role of ""gatekeeper"" mutations V654A and T670I of c-kit kinase in the interaction with inhibitors by means mixed molecular dynamics/docking approach."

PMID 22160160 2012 High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.

PMID 21159146 2011 V559A and N822I double KIT mutant melanoma with predictable response to imatinib?

rs10739221 in LINC01505 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs187843643 in LINC02218 gene and melanoma PMID 28212542 2017 In addition, we uncover a novel polymorphism, rs187843643 (OR = 1.96; 95% CI = [1.54, 2.48]; P = 3.53 x 10-8), associated with melanoma.

rs17119461 in LINC02627 gene and melanoma PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

rs2353033 in LOC100287036;ANKRD11 gene and melanoma PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

rs1126809 in LOC107984363;TYR gene and melanoma PMID 24980573 2014 Identification of a melanoma susceptibility locus and somatic mutation in TET2.

PMID 19578364 2009 Genome-wide association study identifies three loci associated with melanoma risk.

PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs1885120 in LOC107985393;MIR499A;MYH7B gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 18488026 2008 Using pooling, we identified a new melanoma risk locus on chromosome 20 (rs910873 and rs1885120), with replication in two further samples (combined P < 1 x 10(-15)).

rs1335510 in LOC107987026 gene and melanoma PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

PMID 21926416 2011 Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.

rs1057519728 in MAP2K1 gene and melanoma PMID 22197931 2011 Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

PMID 23569304 2013 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

PMID 19915144 2009 MEK1 mutations confer resistance to MEK and B-RAF inhibition.

PMID 22588879 2012 Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

PMID 21383288 2011 Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

PMID 24448821 2014 We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.

PMID 22622578 2012 Melanoma genome sequencing reveals frequent PREX2 mutations.

PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

PMID 21107320 2010 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

PMID 19915144 2009 One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 23444215 2013 Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

rs1057519806 in MAP2K2 gene and melanoma PMID 24265153 2014 The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

PMID 24265154 2014 MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

rs1805007 in MC1R gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs10757257 in MTAP gene and melanoma PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 19578364 2009 Genome-wide association study identifies three loci associated with melanoma risk.

rs45430 in MX2 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

rs4911442 in NCOA6 gene and melanoma PMID 18488026 2008 Common sequence variants on 20q11.22 confer melanoma susceptibility.

rs1204552 in NORAD gene and melanoma PMID 18488026 2008 Common sequence variants on 20q11.22 confer melanoma susceptibility.

rs1057519695 in NRAS gene and melanoma PMID 8120410 1994 Ras mutations in human melanoma: a marker of malignant progression.

PMID 23538902 2013 Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

PMID 2674680 1989 N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

PMID 22761467 2012 First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

PMID 23569304 2013 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

PMID 20179705 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

PMID 23414587 2013 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

PMID 20406486 2010 Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 20130576 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

PMID 18390968 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

PMID 16291983 2005 Distinct sets of genetic alterations in melanoma.

PMID 20149136 2010 Furthermore, PLX4032 increased the rate of proliferation of growth factor-dependent NRAS Q61L mutant primary melanoma cells, reduced cell adherence and increased mobility of cells from advanced lesions.

PMID 21576590 2011 NRAS-mutant melanoma: response to chemotherapy.

PMID 21107323 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

PMID 22962325 2012 Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

PMID 18375819 2008 BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

PMID 23431193 2013 Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

PMID 24918823 2014 Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

PMID 23076151 2012 We generated mutant BRAF(V600E) melanoma cells that exhibit resistance to PLX4720, the tool compound for vemurafenib, that co-expressed mutant (Q61K) NRAS.

PMID 23076151 2012 SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

rs4778138 in OCA2 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs3219090 in PARP1 gene and melanoma PMID 21983785 2011 We also show evidence suggesting that melanoma associates with 1q42.12 (rs3219090, P = 9.3 × 10(-8)).

rs1057519811 in PDGFRA gene and melanoma PMID 24132921 2013 Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

rs6058339 in PHF20 gene and melanoma PMID 18488026 2008 Common sequence variants on 20q11.22 confer melanoma susceptibility.

rs910873 in PIGU gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 18488026 2008 Using pooling, we identified a new melanoma risk locus on chromosome 20 (rs910873 and rs1885120), with replication in two further samples (combined P < 1 x 10(-15)).

rs121913274 in PIK3CA gene and melanoma PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 24265155 2014 Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

rs132985 in PLA2G6 gene and melanoma PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

PMID 19578364 2009 Genome-wide association study identifies three loci associated with melanoma risk.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs1057519815 in RAF1 gene and melanoma PMID 23737487 2013 C-RAF mutations confer resistance to RAF inhibitors.

rs2284378 in RALY gene and melanoma PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs6750047 in RMDN2 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs16891982 in SLC45A2 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

PMID 21983787 2011 Genome-wide association study identifies three new melanoma susceptibility loci.

rs1057519735 in SNAPC5;MAP2K1 gene and melanoma PMID 22197931 2011 Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

rs7188458 in SPATA33 gene and melanoma PMID 21706340 2012 A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

rs121913315 in STK11 gene and melanoma PMID 10208439 1999 Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma.

rs2995264 in STN1 gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs139996880 in TERT gene and melanoma PMID 28212542 2017 Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.

rs4698934 in TET2;TET2-AS1 gene and melanoma PMID 24980573 2014 The SNP rs4698934 was nominally significantly associated with melanoma risk.